About Upstream Bio
Upstream Bio is a publicly listed company based in Waltham (United States) founded in 2021 by Oren Becker. It operates as a therapeutics for allergic and inflammatory diseases are developed. Upstream Bio has raised $400 million across 2 funding rounds from investors including Orbimed, HBM Healthcare Investments and Enavate Sciences. The company has 52 employees. Upstream Bio offers products and services including Verekitug. Its focus areas include Life Sciences, Immunology, Drugs and Inflammatory Diseases. Its competitors include Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna and 3 more; 8 of its 8 listed competitors have raised funding.
Company details
Upstream Bio was founded in 2021 and is headquartered in Waltham, United States. Therapeutics targeting allergic and inflammatory diseases are developed by the company within the biotechnology sector. Operations focus on monoclonal antibodies, with the lead candidate UPB-101 designed to inhibit the TSLP receptor on various immune cells involved in inflammatory conditions. Research and development activities are centered on advancing these treatments for multiple disease indications.
- Headquarters Waltham, United States
- Employees 52
- Founders Oren Becker
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website upstreambio.com
- Social LinkedIn X
- Legal Name Upstream Bio, Inc.
- Annual Revenue$2.85 M (USD)20.42as on Dec 31, 2025
- Net Profit-$143.44 M (USD)-128.39as on Dec 31, 2025
- EBITDA-$160.17 M (USD)-106.21as on Dec 31, 2025
- Total Equity Funding$400M (USD)
in 2 rounds
- Latest Funding Round$200M (USD), Series B
Jun 2023
- InvestorsOrbimed
& 12 more
- Employee Count52
Products & Services of Upstream Bio
Upstream Bio offers a comprehensive portfolio of products and services, including Verekitug.
Targets upstream drivers of inflammatory responses for disease treatment.
Funding Insights of Upstream Bio
Upstream Bio has successfully raised a total of $400M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $200 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $400M
- Total Rounds 2
- Last Round Series B — $200M
- First Round $200M
(Jun 2022)
- Investors Count 13
All 2 funding rounds of Upstream Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2023 | $200M | Series B | – | Enavate Sciences, Venrock | |
| Jun 2022 | $200M | Series A | – | Maruho, Orbimed |
13 investors in total: 13 institutional.
Investors in Upstream Bio
Upstream Bio has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Orbimed, HBM Healthcare Investments and Enavate Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
VC & PE firm focused on healthcare sector | – | venrockcp.com | Palo Alto, United States | |
Investments are focused on pharmaceutical, biotechnology, and medical sectors. | – | baincapitallifesciences.com | Boston, United States | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital firm focused on life science and technology sectors | – | decheng.com | Shanghai, China | |
- | – | tcgcrossover.com | - | |
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
Venture capital firm | – | omegafunds.com | Boston, United States | |
Venture capital funding is provided by Samsara BioCapital in California. | – | samsaracap.com | Palo Alto, United States | |
Investment and holding company controlled by Len Blavatnik | – | accessindustries.com | New York, United States | |
Drug discovery, development, and market assessment consulting services are provided. | 2022 | enavatesciences.com | United States |
Investor details for Upstream Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Upstream Bio
17 people are tracked at Upstream Bio (14 in leadership, 3 in team); the tracked headcount is 52.
| Name | Role | Group |
|---|---|---|
Oren Becker | Founder | Leadership |
James Lee | Senior Medical Director, Clinical Development | Leadership |
Maryse C. | Vp, Head Of Clinical Operations | Leadership |
Kathy Drozd | Sr. Director, Clinical Operations Indication Lead | Leadership |
Rebecca Nuzzo | Sr. Director, Clinical Operations Indication Lead At Upstream Bio | Leadership |
Shea Clingerman | Director, Clinical Operations | Leadership |
Parika Petaipimol | Head Of Technical Operations | Leadership |
Aaron Deykin | Chief Medical Officer And Head Of Research And Development | Leadership |
Ashish Kalra | Head Of Translational Research | Leadership |
Maria Floros | Executive Assistant To CMO And CTO | Leadership |
Fang Xie | Vice President Head Of Biometrics | Leadership |
Sumathi Sivapalasingam M.D. | Vice President Head Of Clinical Development | Leadership |
Olivia Smith | Director Of Program Management | Leadership |
Arkadeep Sinha | Director | Leadership |
Christine Lin | Senior Manager, CMC | Team |
Mersedeh Miraliakbari Pharmd, Rph | Program Lead | Team |
Kanyaphat Bunchongprasert (Wow) | Senior Manager, Analytical | Team |
Complete people profiles for Upstream Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Upstream Bio
Upstream Bio is a publicly listed company on the NASDAQ with ticker symbol UPB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Oct 2024
- Listed onNASDAQ: UPB
- Listed entityUpstream Bio, Inc.
- Exchange sectorHealth technology
- ISINUS91678A1079
- Share price$3.55 (-14.87% on the day) · 2026-10-13
- Market capitalisation$194.4M
- EPS (diluted, trailing year)$-2.89
- Volume (last session)1,037,523
Financials of Upstream Bio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $2.9M | -$143.4M | -$160.2M |
| 2024 | $2.4M | -$62.8M | -$77.7M |
| 2023 | $2.4M | -$20.5M | -$40.0M |
| 2022 | $1.2M | -$23.9M | -$23.9M |
Detailed financial statements for Upstream Bio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Upstream Bio
4 dated milestones of Upstream Bio across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Upstream Bio is founded.
- Funding First funding round of $200.0M.
- Funding Latest funding round, Series B, of $200.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Upstream Bio
Upstream Bio has 8 listed competitors in our database, 8 of them funded. They include Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| escientpharma.com | 2017 | San Diego, United States | $237.5M | 44 | Small molecule therapeutics for inflammatory diseases are developed. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| alpineimmunesciences.com | 2015 | Seattle, United States | $49.25M | 126 | Developer of immunotherapies to treat cancer and autoimmune disorders | |
| septerna.com | 2020 | San Bruno, United States | $250M | – | GPCR drug discovery platform is developed for multiple diseases. | |
| acelyrin.com | 2020 | Los Angeles, United States | $550M | – | Immunological drug candidates are developed for severe diseases. | |
| gossamerbio.com | 2017 | San Diego, United States | $330M | 102 | Developer of small molecule-based therapies for treating immunological disorders, inflammation, and cancer | |
| calcimedica.com | 2006 | San Diego, United States | $76.66M | 11 | CRAC channel inhibitors are developed for inflammatory diseases. |
Detailed competitors of Upstream Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Upstream Bio
The website of Upstream Bio (upstreambio.com) receives about 5.5K visits a month.
- Monthly visits5.5K
▲ 6.8% vs previous month
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as Upstream Bio (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Upstream Bio
Complete news archive for Upstream Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Upstream Bio
Upstream Bio was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Upstream Bio is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Upstream Bio is a funded company, having raised a total of $400M across 2 funding rounds to date. The company's 1st funding round was a Series A of $200M, raised on Jun 2022.
Upstream Bio has 52 employees.
Annual revenue of Upstream Bio is $2.85M as on Dec 31, 2025.
Upstream Bio was founded in 2021 and is headquartered in Waltham, United States. Therapeutics targeting allergic and inflammatory diseases are developed by the company within the biotechnology sector. Operations focus on monoclonal antibodies, with the lead candidate UPB-101 designed to inhibit the TSLP receptor on various immune cells involved in inflammatory conditions. Research and development activities are centered on advancing these treatments for multiple disease indications.
Upstream Bio's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
Upstream Bio offers Verekitug.
Yes, Upstream Bio is publicly traded on NASDAQ under the ticker symbol UPB.
Upstream Bio has 13 investors. Key investors include Orbimed, HBM Healthcare Investments, Enavate Sciences, Altshuler Shaham, and Venrock Capital Partners.